Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 178
Healthy volunteers: yes

Brief summary:
The purposes of this study are:

* To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A)
* To measure how much of the Galcanezumab lyophilized (freeze dried) injectable formulation is absorbed into the blood stream and how long it takes the body to get rid of it compared to the Galcanezumab solution injectable formulation after a single injection under the skin (subcutaneous \[SC\]) (Part B).

Information about any side effects that may occur will also be collected. Each part of the study will last about six months. Participants may only enroll in one part.

Detailed description:

Arms:
arm 1: Galcanezumab solution formulation in a prefilled syringe given SC once. arm 2: Placebo in a prefilled syringe given SC once. arm 3: Galcanezumab lyophilized (freeze dried) formulation given SC once. arm 4: Galcanezumab solution formulation in a prefilled syringe given SC once.

Interventions: intervention 1: Galcanezumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered SC

Protocol document: